Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Completed · Phase 3

Conditions studied: Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism

In brief

This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial

Key facts

Study ID

NCT02064439

Run by

Bayer

People needed

3365

Starts

2014-03-05

Expected to finish

2016-11-04

Last updated by the study team

2017-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with confirmed symptomatic PE and/or DVT who have been treated for 6 to 12 months and did not interrupt anticoagulation for longer than 1 week

You may not qualify if…

• Legal lower age limitations (country specific) Indication for therapeutic-dosed anticoagulants Indication for antiplatelet therapy or a conventional non-steroid anti-inflammatory drug (NSAID) Hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk Calculated creatinine clearance < 30 mL/min

Where it is running

• Study site — La Jolla, California, United States
• Study site — Ventura, California, United States
• Study site — Denver, Colorado, United States
• Study site — Jacksonville, Florida, United States
• Study site — Columbus, Georgia, United States
• Study site — Joliet, Illinois, United States
• Study site — Rockport, Maine, United States
• Study site — Boston, Massachusetts, United States
• Study site — Boston, Massachusetts, United States
• Study site — Boston, Massachusetts, United States
• Study site — Detroit, Michigan, United States
• Study site — Butte, Montana, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Raleigh, North Carolina, United States
• Study site — Columbus, Ohio, United States
• Study site — Toledo, Ohio, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — San Antonio, Texas, United States
• Study site — Fredericksburg, Virginia, United States
• Study site — Bellevue, Washington, United States
• Study site — Seattle, Washington, United States
• Study site — Spokane, Washington, United States
• Study site — Tacoma, Washington, United States
• Study site — Garran, Australian Capital Territory, Australia
• Study site — Beverly Hills, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.